scorecardresearch
The new pecking order in Indian pharma

The new pecking order in Indian pharma

With Sun Pharma acquiring Ranbaxy in a $4 billion deal, the combined entity becomes the market leader in India displacing Abbott Laboratories, with its market share a shade short of 10 per cent. Formerly Sun Pharma was the second-largest company, while Ranbaxy stood at No. 5.

With Sun Pharma acquiring Ranbaxy in a $4 billion deal, the combined entity becomes the market leader in India displacing Abbott Laboratories, with its market share a shade short of 10 per cent. Formerly Sun Pharma was the second-largest company, while Ranbaxy stood at No. 5.

Here is the new pecking order, based on total secondary sales (sales by pharma stockists) with the annual secondary sales figure mentioned in brackets.

1. Sun Pharma + Ranbaxy (Rs 6,921 crore).

2. Abbott (Rs 4,857 crore)

3. Cipla (Rs 3,743 crore)

4. Zydus (Rs 3,334 crore)

5. GSK (Rs 2,771 crore)

6. Mankind (Rs 2,675 crore)

7. Alkem (Rs 2,624 crore)

8. Lupin (Rs 2,514 crore)

9. Pfizer (Rs 2,198 crore)

10. Emcure (Rs 2,112 crore).

With the Sun Pharma-Ranbaxy deal, 77.2 per cent of total secondary sales of medicines from stockists in India will now come from Indian companies. The near reverse was the case when Abbott was market leader.

Source: AIOCD-AWACS database